The Research Park at Florida Atlantic University and Florida Atlantic University’s Schmidt College of Medicine are partnering with Thema Brain Health, a cognitive brain health center at the Research Park, with the goal of preventing Alzheimer’s disease and other related dementias.
Thema Brain Health aims to empower patients to take control of their brain health and it provides information on taking early remedial action. Also, it is likely that Thema Brain Health will become a training site for the university’s medical students and resident physicians.
Orthodontists open new practice in Delray Beach
Drs. Janet Stoess-Allen and Kevin McCaffrey have partnered to establish Delray Orthodontics, 10 SE First Ave., Suite D, Delray Beach. They are ranked as Diamond Plus Invisalign providers, and their practice uses cutting-edge technology. They aim to create a comfortable and efficient patient experience. They invite patients affected by the recent closure of Smile Direct Club to join them to continue their orthodontic treatment.
JFK Hospital opens doors for volunteer activities
After a long hiatus, volunteers are welcomed back to HCA Florida JFK Hospital.
Volunteers contribute by assisting in the lobby, taking on administrative tasks, providing companionship to patients and offering emotional support to families. Schedules are flexible.
Volunteers must be 15 or older, complete an application and background check, and attend an orientation. To learn more, call the hospital’s volunteer services manager, Christie Lee Geltz, at 561-548-1357 or email Christielee.Geltz@hcahealthcare.com
Alzheimer’s drug trial put on hold by FDA
InMune Bio’s phase-two clinical trial for the Alzheimer’s disease drug XPro is on hold after the U.S. Food and Drug Administration requested additional information about its long-term potency. In a statement, Boca Raton-based InMune Bio reported that it will provide clarification to the FDA before the end of the year to resolve questions.
“The hold will not impact our progress in completing the Phase II AD study on schedule,” CEO R.J. Tesi said in the statement. The clinical trial is still open in Australia, Canada, the United Kingdom, Poland, France and Spain and is expected to launch in additional European Union countries.
Send health news to Christine Davis at firstname.lastname@example.org.